Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALAWAY versus LASTACAFT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALAWAY versus LASTACAFT.
CHILDREN'S ALAWAY vs LASTACAFT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of H1 histamine receptors, inhibiting histamine-mediated allergic responses; also blocks muscarinic acetylcholine receptors, contributing to anticholinergic effects.
Selective histamine H1 receptor antagonist; inhibits mast cell degranulation and reduces release of inflammatory mediators.
Children's Alaway (ketotifen fumarate ophthalmic solution) is approved for children aged 3 years and older. The typical dose is 1 drop in the affected eye(s) twice daily, approximately every 8-12 hours. There is no standard adult dose as the product is indicated only for pediatric use.
1 drop in each affected eye twice daily (approximately every 8 hours)
None Documented
None Documented
Terminal elimination half-life 2.5–3.5 hours in children; prolonged in renal impairment or neonates.
Terminal elimination half-life is approximately 2 hours; clinically, dosing is twice daily.
Primarily renal (approx. 90%) as unchanged drug and glucuronide conjugates; minimal biliary/fecal elimination (<5%).
Renal: approximately 70% as unchanged drug; fecal: approximately 30% as metabolites.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine